Background
Mast cells are hematopoietically derived cells that reside in the connective tissue [
1‐
5] and play a major role in the immune response in both physiological and pathological processes such as allergy, inflammation, cardiac disease, cancer, autoimmune diseases, and wound healing [
6‐
9]. The activation of mast cells in these processes results in degranulation, release of lipid mediators and cytokines [
10]. The mast cell mediators then recruit other cell types including T lymphocytes, neutrophils, and dendritic cells to inflammatory sites [
11‐
13].
Lectins are among the diverse molecules that have been shown to activate mast cells [
14‐
16]. It has previously been shown that the native tetrameric ArtinM (jArtinM), a D-mannose-binding lectin from
Artocarpus heterophyllus (jackfruit) seeds, induces the recruitment of rat mast cells from bone marrow to the peritoneal cavity [
17], as well as inducing degranulation of rat peritoneal mast cells [
11]. In the rat mast cell line RBL-2H3, jArtinM stimulates NFAT (nuclear factor of activated T-cells) and NFkB (nuclear factor kappa-light-chain-enhancer of activated B cells) in an IgE independent manner [
18]. In addition to its action on mast cells, jArtinM also recruits neutrophils [
19] by binding to glycans of CXCR2 that stimulate signal transduction via G protein [
20], thus activating the cells and increasing their phagocytic activity against pathogens [
21]. jArtinM also has immunomodulatory activity. Systemic administration of jArtinM confers protection against intracellular parasites such as
Leishmania major and
Paracoccidioides brasiliensis, by inducing IL-12 production through interaction with TLR2 N-glycans, resulting in a Th1-type immune response [
22,
23].
A recombinant form of jArtinM, rArtinM, has been heterologously expressed in
Escherichia coli [
24,
25]. rArtinM is produced as soluble monomers with its CRDs preserved and active [
25]. Furthermore, the binding affinity of rArtinM to the trimannoside Manα1-3 [Manα1-6] Man from HRP, a N-glycosylated protein, is similar to the native form [
26]. Additionally, rArtinM showed both prophylactic and therapeutic effects during the course of
P. brasiliensis infection in mice [
27]. The present investigation was undertaken to evaluate if rArtinM, as a monomeric molecule, has the same ability as jArtinM to activate mast cells. In the current study, rArtinM was shown to have the same binding affinity to N-glycans as the native form, jArtinM, and was also able to activate and degranulate mast cells through its CRDs.
Discussion
The present study shows that the recombinant monomeric form of ArtinM, rArtinM, expressed in Escherichia coli, has the ability to induce mast cell activation and degranulation. Activation by rArtinM resulted in the release of preformed, newly formed, and newly-synthesized mediators. Also, mast cell activation triggered by rArtinM results in morphological changes that are characteristic of activated mast cells. Furthermore, mast cell activation induced by rArtinM is dependent on its CRDs. Additionally, the IgE-dependent activation of mast cells triggered by rArtinM is dependent on NFkB activation.
The ubiquitous distribution of mast cells places them in a privileged position to act as sentinel cells, responding rapidly to external signals by releasing their stored preformed mediators and secreting newl
y-synthesized lipid mediators [
10]. One of the principal preformed mediators released during mast cell degranulation is TNF-α [
6,
33]. TNF-α is an important chemoattractant for neutrophils and T cells during inflammatory processes [
11,
34‐
36]. Besides TNF-α, leukotrienes also play a role in recruiting neutrophils and T cells to sites of inflammation [
7,
37]. The release of TNF-α and LTC4 induced by rArtinM may help explain some of the biological activities attributed to this lectin such as accelerated tissue regeneration [
38,
39] and amplified recruitment of neutrophils [
11].
It has been shown previously that monomers of rArtinM share their primary structure with the native form of ArtinM (jArtinM), which contributes to its correct folding and exposure of its CRDs, leading to its proper lectin-like activity [
25]. This data supports our current findings showing that the ability of rArtinM to activate and degranulate mast cells is dependent on their CRDs.
The fact that rArtinM is expressed as monomers and is able to oligomerize in solution, most likely because of a high monomer concentration, supports our findings, since mast cell activation and degranulation occurred at high concentrations of rArtinM. A similar dose-dependent effect was observed when rArtinM was assayed for its effect on spleen cells. In spleen cells, only high concentrations of rArtinM induced cell proliferation and IL-2 production [
40]. Although it shares the sugar-binding specificity of jArtinM, rArtinM differs in its avidity for glycotargets due to its unique quaternary structure. The requirement for high concentrations of rArtinM in order to trigger cellular responses may be associated with its oligomerization upon binding to glycoligands on the cell surface, as has been well established for Galectin 3 [
41]. Both IgE [
42] and FcεRI [
43] are highly glycosylated. IgE contains several mannose residues that could be targets for ArtinM [
44,
45]. FcεRI, also presents structural characteristics that could favor its recognition by ArtinM such as several N- glycosylation sites on the FcεRI α subunit [
46]. Therefore, rArtinM may be activating mast cells by cross-linking IgE or FcεRI.
However, previous studies have demonstrated that jArtinM is able to degranulate the rat mast cell line, RBL-2H3, as well as peritoneal rat mast cells in an IgE-independent manner [
11,
18]. The possibility that rArtinM interacts with other receptors on the mast cell surface, such as TLR4 [
6,
47], TLR2 [
48,
49], the chemokine receptor CXCR2 [
50‐
52] and complement receptors [
7], should not be completely discounted, since degranulation, IL-4 release and the morphological changes on the mast cell surface triggered by rArtinM all occurred in an IgE-independent manner.
It is well established that mast cells can respond in different manners to the same stimulus. For example, FcεRI cross-linking results in NFkB activation leading to mast cell degranulation [
53]. However, exposure of IgE sensitized mast cells to low concentrations of specific antigen induces NFAT activation in the absence of degranulation [
54]. The same appears to be true for ArtinM. At 10 μg/ml, jArtinM induces mast cell degranulation as well as NFkB and NFAT activation [
18], while rArtinM at the same concentration does not induce degranulation. The fact that rArtinM can activate mast cells in a pro-inflammatory manner, without inducing degranulation, makes it an attractive candidate for pharmacological use.
rArtinM was also able to induce IL-4 release. It is known that IL-4 and another cytokines such as, IL-6, VEGF, IL-13 and, TNF-α play a role in allergic inflammatory processes, leading to IgE production by B cells [
55,
56]. The ability of rArtinM to induce IL-4 release agrees with our previous data showing that ArtinM can trigger an allergic pro-inflammatory response [
11,
18]. However, higher concentrations of rArtinM (20 and 40 μg/ml) were required to trigger responses similar to those observed for jArtinM [
18].
Methods
rArtinM preparations
rArtinM was expressed in
Escherichia coli BL21- CodonPlus(DE3)-RP and purified as previously reported [
25]. rArtinM preparations containing less than 0.05 ng/ml of bacterial endotoxin, as determined by the
Limulus amoebocyte lysate assay, were used in this study (Sigma-Aldrich., St. Louis, MO).
Size exclusion chromatography
Native and recombinant forms of ArtinM were submitted to size exclusion chromatography for molecular weight determination, on a Superdex 75 column (Sigma Aldrich) coupled to an AKTA protein purification system (GE Healthcare, Uppsala, Sweden), which was calibrated by using protein molecular weight standards (Protein Mixture, GE Healthcare). The molecular weight of proteins was determined by partition coefficient (Kav) using this formula: Kav = Ve-Vo/Vt-Vo, where Ve is the elution volume of the samples, Vt is the total volume and Vo is the void volume of the gel bed. High molecular weight blue dextran was used to determine the void volume.
Analytical ultracentrifugation
Sedimentation velocity measurements were performed using a Beckman XL-A analytical centrifuge equipped with both absorbance and interference optics. All data were acquired at a rotor-speed of 50,000 rpm at 20 °C using a Beckman An60Ti rotor. For each sample, 100 scans were acquired at 120 s intervals. Buffer density and viscosity as well as the partial specific volume of the protein were calculated using SEDNTERP (Alliance Protein Laboratories, Thousand Oaks, CA,).
Glycan array analysis
The native and recombinant ArtinM forms were biotinylated as previously described [
38] and quantified by determining their absorbance at 280 nm (OD280). Microarrays were composed of lipid-linked oligosaccharide probes robotically printed in duplicate on nitrocellulose-coated glass slides at 2 and 7 fmol per spot (in-house designation sets 18–21bis) using a non-contact instrument, as previously described [
57]. The microarray binding assays of biotinylated ArtinM proteins were performed at 19 °C–20 °C, as previously described [
58]. In brief, the slide arrays were blocked with 1 % w/v bovine serum albumin (Sigma Aldrich) in casein blocking solution (Pierce Chemical Co, Thermo Fisher, Waltham, MA) for 1 h. The biotinylated ArtinM (50 μg/mL) was overlaid, and binding was detected with streptavidin conjugated to Alexa Fluor 647 (Molecular Probes, Thermo Fisher, Waltham, MA) at 1 μg/mL in blocking solution. Glycoarray data analysis was performed with dedicated software [
59]. The binding signals were probe-dose dependent.
Cells
RBL-2H3 cells, a rat mast cell line, were used in this study [
60]. The stable transgenic RBL-2H3 derived cell lines, VB9 and NFkB 2, were also used. The VB9 cell line is a GFP- reporter cell line for NFAT activation [
54]. The NFkB 2 cell line is a GFP-reporter cell line for NFkB activation [
61], which presents a genome transduction with a reporter vector that possess 4 copies of the binding site for NFkB that regulate GFP expression. All cells were grown as monolayers in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Thermo Fisher, Waltham, MA) supplemented with 15 % fetal calf serum (Sigma-Aldrich) as previously described [
60]. Transfected cells were selected with geneticin (0.4 mg/ml) (Sigma-Aldrich). All cell lines were generously provided by Dr. Reuben P. Siraganian, NIDCR, NIH, Bethesda, MD.
Cell sensitization and stimulation
As a positive control for FcεRI stimulated cells, the cells were cultured in the presence of a 1:5000 dilution of mouse IgE anti-TNP ascites fluid (kindly provided by Dr. Reuben P. Siraganian) for 16 h, and then stimulated with the multivalent specific antigen DNP48-HSA (Sigma-Aldrich) at 50 ng/ml. As positive control for FcεRI-independent stimulation, the cells were incubated with calcium ionophore-A23187 (Sigma-Aldrich) at 0.1 μM for degranulation assays and, at 0.7 μM for NFkB and NFAT activation assays. In experimental conditions, the cells were sensitized or not with IgE anti-TNP ascites fluid (1:5000) for 16 h and then stimulated with rArtinM. In some experiments, rArtinM was preincubated with D-mannose 100 mM (Sigma-Aldrich) for 1 h at 4 °C. To evaluate release of preformed mediators (β-hexosaminidase and TNF-α) and the lipid mediator LTC4, cells were stimulated for 45 min. For scanning electron microscopy, the cells were stimulated for 20 min. For newly-synthesized IL-4, the cells were stimulated for 12 h. For NFkB and NFAT activation, the cells were stimulated for 5 and 17 h respectively.
β-Hexosaminidase activity
3.0 × 10
4 cells/well were plated in 96 well tissue culture plates (Corning Life Sciences, Lowell, MA) in the absence or presence of IgE and cultured overnight. The cells were washed 2 times with Tyrode’s buffer (137 mM NaCl; 2.7 mM KCl; 12 mM NaHCO
3; 0.37 mM NaH
2PO
4; 0.1 mM MgCl
2; 1.3 mM CaCl
2; 10 mM Hepes, pH 7.3) supplemented with 0.1 % BSA (Sigma-Aldrich) and 0.01 % gelatin (Sigma-Aldrich) and then incubated with the stimulus diluted in Tyrode’s buffer for 45 min as described above in
Cell sensitization and stimulation. After stimulation, the supernatants were transferred to clean wells and β-hexosaminidase activity measured as previously described [
1]. All assays were run in triplicate.
Leukotriene C4 and cytokine detection assays
IgE-sensitized or unsensitized cells were incubated with rArtinM for 45 min or 12 h. The concentrations of LTC4, TNF-α and IL-4 in the cell culture supernatants were measured by ELISA (Leukotriene C4 EIA kit, Cayman Chemical Company, MI, USA; OPTEIA™ Rat TNF ELISA kit II; OPTEIA™ Rat IL-4 ELISA kit II, BD Biosciences, San Jose, CA) according to the manufacturer’s instructions.
Scanning electron microscopy (SEM)
Cells (3x10
4) were cultured on 13 mm diameter glass coverslips in 24 well plates (Corning Life Sciences). The cells were cultured in the presence or absence of IgE for 16 h. The cells were then stimulated as described in
Cell sensitization and stimulation. The samples were prepared as previously described [
62], and were examined with a JEOL JSM-6610 LV scanning electron microscope (JEOL, Ltd.; Tokyo, Japan).
Flow cytometric measurements of NFkB and NFAT activation
NFkB2 and VB9 cells (1x105) were sensitized or not with IgE, and then stimulated. Fluorescence levels were measured using a Guava Personal Cell Analysis-96 System and data were processed by Guava InCyte Software (Millipore Co., Billerica, MA).
Statistics
Data was analyzed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Results were expressed as mean ± SEM. Differences between groups were assessed by one-way ANOVA followed by Tukey’s Multiple Comparison Test. *p < 0.05; **p < 0.01; ***p < 0.001.
Abbreviations
CRD, carbohydrate recognition domain; TNF-α, tumor necrosis factor alpha; IgE, immunoglobulin E; NFkB, nuclear factor kappa B; NFAT, nuclear factor of activated T-cells; RBL-2H3, rat basophilic leukemia cell line; CXCR2, chemokine receptor 2; HRP, horseradish peroxidase; TLR2, toll like receptor 2; AUC, analytical ultracentrifugation; LTC4, leukotriene C 4; SEM, scanning electron microscopy; FcεRI, high affinity receptor for IgE; VEGF, vascular endothelial growth factor; kD, kilodaltons; MW, molecular weight
Acknowledgements
We would like to thank Anderson R. Souza and Sandra M. O. Thomaz for technical support. We also thank José A. Maulin, Maria Dolores S. Ferreira, and Maria Teresa P. Maglia (Laboratório Multiusuário de Microscopia Eletrônica) for support and assistance with the scanning electron microscopy. We would also like to thank Edismauro Garcia Freitas Filho for FACS sorting the NFkB 2 and VB9 cell lines. All personnel are from the Department of Cell and Molecular Biology and Pathogenic. We are grateful to the collaborators who provided saccharides for the microarrays and to the members of the Glycosciences Laboratory of Imperial College London (UK) for their collaboration in the establishment of the neoglycolipid-based microarray system, especially Dr. Ten Feizi and Dr.Yan Liu, and Dr. Fernanda Caroline de Carvalho. We also thank Dr. Nicholas Gay and Dr. Martin Moncrieffe for help with AUC experiments.